Drug intelligence / Profile preview

PB922

Development stage: Preclinical
Lead developer: PEG Biosciences

Overview

PB922 is an anti-inflammatory biological product developed by PEG Biosciences for the treatment of autoimmune diseases, including multiple sclerosis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. The drug is designed as an enhanced biological system that regulates cytokine production and modulates T cell proliferation. It is built upon PEG Biosciences' proprietary BioSynersys™ and ProbioTherapeutic™ technology platforms, which aim to address unmet medical needs through innovative therapeutic formulations.

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on PB922.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB922.

Explore the full profile